Galectin-3 Mediates Nuclear β-Catenin Accumulation and Wnt Signaling in Human Colon Cancer Cells by Regulation of Glycogen Synthase Kinase-3β Activity
Open Access
- 12 February 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (4), 1343-1349
- https://doi.org/10.1158/0008-5472.can-08-4153
Abstract
Wnt/β-catenin signaling plays an essential role in colon carcinogenesis. Galectin-3, a β-galactoside–binding protein, has been implicated in Wnt signaling, but the precise mechanisms by which galectin-3 modulates the Wnt pathway are unknown. In the present study, we determined the effects of galectin-3 on the Wnt/β-catenin pathway in colon cancer cells, as well as the mechanisms involved. Galectin-3 levels were manipulated in human colon cancer cells by stable transfection of galectin-3 antisense, short hairpin RNA, or full-length galectin-3 cDNA, and effects on β-catenin levels, subcellular distribution, and Wnt signaling were determined. Galectin-3 levels correlated with β-catenin levels in a variety of colon cancer cell lines. Down-regulation of galectin-3 resulted in decreased β-catenin protein levels but no change in β-catenin mRNA levels, suggesting that galectin-3 modulates β-catenin by another mechanism. Reduction of galectin-3 led to reduced nuclear β-catenin with a concomitant decrease in TCF4 transcriptional activity and expression of its target genes. Conversely, transfection of galectin-3 cDNA into colon cancer cells increased β-catenin expression and TCF4 transcriptional activity. Down-regulation of galectin-3 resulted in AKT and glycogen synthase kinase-3β (GSK-3β) dephosphorylation and increased GSK activity, increasing β-catenin phosphorylation and degradation. Ly294002, an inhibitor of phosphatidylinositol 3-kinase, and dominant-negative AKT, suppressed TCF4 transcriptional activity induced by galectin-3 whereas LiCl, a GSK-3β inhibitor, increased TCF4 activity, mimicking the effects of galectin-3. These results suggest that galectin-3 mediates Wnt signaling, at least in part, by regulating GSK-3β phosphorylation and activity via the phosphatidylinositol 3-kinase/AKT pathway, and, thus, the degradation of β-catenin in colon cancer cells. [Cancer Res 2009;69(4):1343–9]Keywords
This publication has 39 references indexed in Scilit:
- Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathwayCancer and Metastasis Reviews, 2007
- Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and ChemosensitizationMolecular and Cellular Biology, 2007
- Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional ActivityOnline Journal of Public Health Informatics, 2007
- Galectin-3 Modulates MUC2 Mucin Expression in Human Colon Cancer Cells at the Level of Transcription via AP-1 ActivationGastroenterology, 2005
- Oncogenic K-ras Stimulates Wnt Signaling in Colon Cancer Through Inhibition of GSK-3βGastroenterology, 2005
- Galectins as modulators of tumour progressionNature Reviews Cancer, 2005
- Wnt-Independent ?-catenin Transactivation in Tumor DevelopementCell Cycle, 2004
- Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activationOncogene, 2001
- Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposisJCI Insight, 2000
- Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase BNature, 1995